UBS analyst Ashwani Verma raised the firm’s price target on Neurocrine (NBIX) to $195 from $188 and keeps a Buy rating on the shares. Investor attention on Neurocrine centers on potential read-through from Medicare price negotiations for Teva’s (TEVA) Austedo, expected by late November, the analyst says in a research note. However, analysis of Ingrezza under IRA frameworks suggests these concerns may be overstated, with projections indicating stronger revenue potential beginning in 2029.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine presents new data from KINECT-HD2 study of ingrezza
- Neurocrine’s ingrezza shows efficacy in tardive dyskinesia
- Promising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine Biosciences
- Neurocrine price target raised to $169 from $160 at Jefferies
- Neurocrine announces Phase 2 SAVITRI met primary efficacy endpoint